CN109939141B - 一种咳特灵胶囊及其制备方法 - Google Patents
一种咳特灵胶囊及其制备方法 Download PDFInfo
- Publication number
- CN109939141B CN109939141B CN201910161799.5A CN201910161799A CN109939141B CN 109939141 B CN109939141 B CN 109939141B CN 201910161799 A CN201910161799 A CN 201910161799A CN 109939141 B CN109939141 B CN 109939141B
- Authority
- CN
- China
- Prior art keywords
- capsule
- powder
- parts
- dry extract
- ficus microcarpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 153
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 133
- 240000000231 Ficus thonningii Species 0.000 claims abstract description 118
- 239000011812 mixed powder Substances 0.000 claims abstract description 75
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 58
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 34
- 239000000654 additive Substances 0.000 claims abstract description 31
- 230000000996 additive effect Effects 0.000 claims abstract description 31
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 17
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 17
- 238000011049 filling Methods 0.000 claims abstract description 12
- 238000003756 stirring Methods 0.000 claims description 38
- 206010011224 Cough Diseases 0.000 claims description 32
- 238000007873 sieving Methods 0.000 claims description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 14
- 235000002906 tartaric acid Nutrition 0.000 claims description 14
- 239000011975 tartaric acid Substances 0.000 claims description 14
- 229920001661 Chitosan Polymers 0.000 claims description 13
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000741 silica gel Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003607 modifier Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 229910021487 silica fume Inorganic materials 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 13
- 229940046978 chlorpheniramine maleate Drugs 0.000 abstract description 10
- 230000000052 comparative effect Effects 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 238000012360 testing method Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 229920002261 Corn starch Polymers 0.000 description 11
- 208000006673 asthma Diseases 0.000 description 11
- 239000008120 corn starch Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 230000000954 anitussive effect Effects 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- 206010006451 bronchitis Diseases 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 206010006458 Bronchitis chronic Diseases 0.000 description 5
- 229940124584 antitussives Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000007451 chronic bronchitis Diseases 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000003434 antitussive agent Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 241000605372 Fritillaria Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000245165 Rhododendron ponticum Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229930013053 morphinan alkaloid Natural products 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 238000009700 powder processing Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
项目 | 实施例1 | 实施例2 | 实施例3 | 对比例1 | 对比例4 |
休止角 | 22.8° | 23.5° | 22.4° | 33.5° | 36.8° |
装量差异限度 | ±4.6% | ±5.2% | ±4.2% | ±6.8% | ±8.0% |
项目 | 实施例1 | 实施例2 | 实施例3 | 对比例2 | 对比例3 |
A+1.8S | 6.4 | 6.6 | 6.2 | 9.5 | 11.2 |
组别 | 小鼠数(只) | 咳嗽潜伏期(S) |
空白对照组 | 10 | 36.15 |
阳性药物对照组 | 10 | 70.24 |
实施例3组 | 10 | 82.45 |
对比例2组 | 10 | 58.37 |
对比例3组 | 10 | 48.32 |
组别 | 小鼠数(只) | 透光率(T%) |
空白对照组 | 10 | 90.38 |
阳性药物对照组 | 10 | 78.65 |
实施例3组 | 10 | 72.48 |
对比例2组 | 10 | 83.22 |
对比例3组 | 10 | 86.13 |
组别 | 豚鼠数(只) | 反应出现时间(S) |
空白对照组 | 10 | 73.34 |
实施例3组 | 10 | 128.36 |
对比例2组 | 10 | 105.42 |
对比例3组 | 10 | 93.15 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910161799.5A CN109939141B (zh) | 2019-03-04 | 2019-03-04 | 一种咳特灵胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910161799.5A CN109939141B (zh) | 2019-03-04 | 2019-03-04 | 一种咳特灵胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109939141A CN109939141A (zh) | 2019-06-28 |
CN109939141B true CN109939141B (zh) | 2021-09-07 |
Family
ID=67008299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910161799.5A Active CN109939141B (zh) | 2019-03-04 | 2019-03-04 | 一种咳特灵胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109939141B (zh) |
-
2019
- 2019-03-04 CN CN201910161799.5A patent/CN109939141B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN109939141A (zh) | 2019-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101574323B (zh) | 一种米格列醇微囊片剂及其制备方法 | |
CN114129527B (zh) | 一种微型片剂及其制备方法和制剂 | |
CN101700227B (zh) | 苦参碱结肠靶向粘附微丸 | |
CN101416947A (zh) | 复方α-酮酸咀嚼片及制备方法 | |
KR101562608B1 (ko) | 호흡기 질환에 작용하는 복합 화학 약물, 그들의 제조 방법 및 용도 | |
CN101926840B (zh) | 一种紫锥菊的超微粉散剂及其制备方法和应用 | |
CN111700874A (zh) | 一种恩诺沙星肠溶速释掩味颗粒剂及其制备方法 | |
CN104146978A (zh) | 一种双硫仑肠溶片剂及其制备方法 | |
CN107375247B (zh) | 替米考星膜控肠溶缓释制剂及其制备方法 | |
CN109939141B (zh) | 一种咳特灵胶囊及其制备方法 | |
CN103191114A (zh) | 一种含有莫西沙星的药物口服固体制剂及其制备方法 | |
CN101791298B (zh) | 一种以果胶/玉米朊为包衣的结肠给药片 | |
CN101991720A (zh) | 结肠宁靶向给药制剂及用途 | |
CN112386578B (zh) | 一种孟鲁司特钠咀嚼片及其制备方法 | |
CN101461853B (zh) | 一种用于镇咳祛痰、平喘的中药颗粒剂及其制备方法 | |
CN105596312A (zh) | 一种磷酸二甲啡烷胶囊组合物及其制备方法 | |
CN113398082A (zh) | 一种盐酸左氧氟沙星片及其制备方法 | |
WO2021258590A1 (zh) | 一种β-葡聚糖作为粘合剂在制备片剂或颗粒剂中的应用 | |
CN114010613B (zh) | 六神丸肠溶制剂及其制备方法 | |
CN1939413B (zh) | 一种复方北豆根药物组合物 | |
CN114376978B (zh) | 一种多索茶碱包芯片及其制备方法 | |
CN101219200A (zh) | 一种中药软胶囊及其制备方法 | |
CN115252566B (zh) | 一种养胃护肝的中药复合片剂及其制备方法 | |
CN104337783B (zh) | 一种卡培他滨片剂及其制备方法 | |
JPH04368330A (ja) | ペミロラストカリウムの徐放性製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 526200 Fengshan Road, Dongcheng District, Sihui City, Guangdong, Zhaoqing Applicant after: Yili Pharmaceutical Co.,Ltd. Address before: 526200 Fengshan Road, Dongcheng District, Sihui City, Guangdong, Zhaoqing Applicant before: GUANGDONG YILI GROUP PHARMACEUTICAL Co.,Ltd. |
|
CB02 | Change of applicant information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Xia Inventor after: Zhang Hao Inventor after: Luo Yunzhang Inventor after: Huang Canlin Inventor after: Liang Fengyan Inventor after: Ling Kangcai Inventor before: Liang Fengyan Inventor before: Zhang Hao Inventor before: Li Xia Inventor before: Huang Canlin Inventor before: Ling Kangcai |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Huang Canlin Inventor after: Li Xia Inventor after: Zhang Hao Inventor after: Luo Yunzhang Inventor after: Liang Fengyan Inventor after: Ling Kangcai Inventor before: Li Xia Inventor before: Zhang Hao Inventor before: Luo Yunzhang Inventor before: Huang Canlin Inventor before: Liang Fengyan Inventor before: Ling Kangcai |
|
CB03 | Change of inventor or designer information |